From magic bullets to designed multiple ligands.

By R. Morphy, C. Kay, Z. Rankovic. Drug Discovery Today, 2004

629 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Network pharmacology: the next paradigm in drug discovery. (2008, background): “have described the continuum of design strategies medicinal chemists have traditionally used to design drugs with multiple activitie”
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity (2011, background): “This parallel approach is predicted to identify unexpected new inhibitors for kinases of interest and reveal multitargeted inhibitors, whose inhibitory activity is focused toward a small number of specific kinase targets rather than toward a single primary targe”
Curcumin as "Curecumin": from kitchen to clinic. (2008, background): “[206] Morphy R, Kay C, Rankovic Z.”
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors (2007, background): “Moreover, although drugs are traditionally optimized against a single protein, many compounds act on multiple target”
In silico pharmacology for drug discovery: applications to targets and beyond (2007, background): “…to ligand and target space in which a lead molecule against one gene family member is used for another similar target (termed chemogenomics) (Morphy et al ., 2004; Sharom et al ., 2004), will be discussed thoroughly in an upcoming review in this journal from Didier Rognan (personal…”